News >

Rucaparib FDA Approval Creates Trifecta of Maintenance PARP Inhibitors in Ovarian Cancer

Caroline Seymour
Published: Tuesday, May 08, 2018

Lyndsay J. Willmott, MD

Lyndsay J. Willmott, MD
There are now 3 FDA-approved PARP inhibitors in the maintenance setting—niraparib (Zejula), olaparib (Lynparza), and rucaparib (Rubraca)—for patients with ovarian cancer who are in a complete or partial response to platinum-based chemotherapy.

The April 2018 approval of rucaparib was based on the results of the phase III ARIEL3 trial, in which 10 patients saw complete responses with rucaparib compared with 1 patient on placebo, leading to an overall response rate of 18%.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x